Similar Papers

Paper Title
Journal
Date
Author
221 CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors
...
Journal for ImmunoTherapy of Cancer | VOL. 9
, et. al. ...
01 Nov 2021
Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.
Stephen Ansell ... Eric Sievers
Blood | VOL. 108
Stephen Ansell, et. al.Stephen Ansell ... Eric Sievers
16 Nov 2006
Investigators aim to increase CAR T-cell research and extend its reach: A new initiative by the National Cancer Institute could help this life-saving treatment reach more patients with advanced cancers.
Carrie Printz
Cancer | VOL. 126
Carrie PrintzCarrie Printz
23 Oct 2020
Abstract 3575: Differential dynamics of response at single cell resolution between axi-cel and tisa-cel CAR-T therapy in refractory B-cell lymphomas
Nicholas J Haradhvala ... Raquel A Jacobs
Cancer Research | VOL. 82
Nicholas J Haradhvala, et. al.Nicholas J Haradhvala ... Raquel A Jacobs
15 Jun 2022
View more papers

More From: Blood Advances

Paper Title
Journal
Date
Author
PRMT5 Inhibition Reduces Hyperinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis (HLH).
Fiona Brown-Burke ... Polina Shindiapina
Blood advances | VOL. -
Fiona Brown-Burke, et. al.Fiona Brown-Burke ... Polina Shindiapina
18 Jan 2025
Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive literature review.
Luke Wang ... Eliza A Hawkes
Blood advances | VOL. -
Luke Wang, et. al.Luke Wang ... Eliza A Hawkes
18 Jan 2025
Characterization of the Phenotypic Consequences of the Duffy-Null Genotype.
Micah R Hysong ... Laura M Raffield
Blood advances | VOL. -
Micah R Hysong, et. al.Micah R Hysong ... Laura M Raffield
18 Jan 2025
Final Analysis of the Phase 1b Chemotherapy And Venetoclax in Elderly Acute Myeloid Leukaemia Trial (CAVEAT).
Chong Chyn Chua ... Andrew H Wei
Blood advances | VOL. -
Chong Chyn Chua, et. al.Chong Chyn Chua ... Andrew H Wei
18 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.